ANALISIS EKSPRESI MMP1 PADA KARSINOMA PAYUDARA INVASIF DENGAN BIOINFORMATIKA MELALUI UALCAN: BIOMARKER PROGNOSTIK POTENSIAL
Analysis of MMP1 Expression in Invasive Breast Carcinoma with Bioinformatics via UALCAN : A Potential Prognostic Biomarker
DOI:
https://doi.org/10.46772/jophus.v7i1.1778Keywords:
MMP1, BRCA, prognostic biomarker, bioinformatics, DNA methylationAbstract
Pendahuluan: Kanker payudara invasif (BRCA) merupakan penyebab utama kematian kanker pada wanita global. Matrix Metalloproteinase-1 (MMP1), enzim pemecah matriks ekstraseluler, diduga berperan dalam invasi dan metastasis BRCA. Penelitian ini bertujuan menganalisis potensi MMP1 sebagai biomarker prognostik BRCA menggunakan pendekatan bioinformatika. Metode: Studi berbasis data TCGA ini menggunakan platform UALCAN untuk menganalisis ekspresi MMP1, metilasi promotor, dan hubungannya dengan parameter klinis. Analisis statistik meliputi uji-t, ANOVA, dan kurva Kaplan-Meier dengan uji log-rank (signifikansi p<0,05). Hasil: Ekspresi MMP1 pada jaringan tumor 5 kali lebih tinggi daripada normal (p<0,001), didukung hipometilasi promotor. Pasien dengan ekspresi tinggi MMP1 menunjukkan survival lebih buruk (p=0,0042). Variasi signifikan terlihat berdasarkan ras (terburuk pada African-American), status menopause (terburuk post-menopause), dan subtipe molekuler (HER2+ dan triple-negatif). Kesimpulan: MMP1 terbukti sebagai biomarker prognostik potensial untuk BRCA dengan implikasi klinis dalam stratifikasi risiko dan terapi target. Temuan ini mendorong penelitian lanjutan untuk validasi klinis dan pengembangan terapi spesifik.
References
Avery A, Alden J, Kramish C, Caballero C, Wright-Void C, Bruner ET. The pathologic diagnosis of carcinoma in various tissues. Adv Cancer Res. 2022;154:1-14. doi: 10.1016/bs.acr.2022.03.001. Epub 2022 Apr 5. PMID: 35459466.
Caglevic C, Anabalón J, Soza C, Milla E, Gaete F, Carrasco AM, Panay S, Gallardo C, Mahave M. Triple-negative breast cancer: the reality in Chile and in Latin America. Ecancermedicalscience. 2019 Jan 22;13:893. doi: 10.3332/ecancer.2019.893. PMID: 30792810; PMCID: PMC6372297.
Olea-Flores M, Juárez-Cruz JC, Mendoza-Catalán MA, Padilla-Benavides T, Navarro-Tito N. Signaling Pathways Induced by Leptin during Epithelial−Mesenchymal Transition in Breast Cancer. Int J Mol Sci. 2018 Nov 6;19(11):3493. doi: 10.3390/ijms19113493. PMID: 30404206; PMCID: PMC6275018.
Le Du F, Moati E, Vaflard P, Bailleux C, Pierga JY, Dieras V. La prise en charge des cancers du sein triple négatifs : état actuel et perspectives [Triple negative breast cancer: Current status and perspectives]. Bull Cancer. 2025 Jan;112(1):82-99. French. doi: 10.1016/j.bulcan.2024.09.002. Epub 2024 Nov 6. PMID: 39510910.
Kou L, Jiang X, Lin X, Huang H, Wang J, Yao Q, Chen R. Matrix Metalloproteinase Inspired Therapeutic Strategies for Bone Diseases. Curr Pharm Biotechnol. 2021;22(4):451-467. doi: 10.2174/1389201021666200630140735. PMID: 32603279.
Mustafa S, Koran S, AlOmair L. Insights Into the Role of Matrix Metalloproteinases in Cancer and its Various Therapeutic Aspects: A Review. Front Mol Biosci. 2022 Sep 29;9:896099. doi: 10.3389/fmolb.2022.896099. PMID: 36250005; PMCID: PMC9557123.
Mao S, Xia A, Tao X, Ye D, Qu J, Sun M, Wei H, Li G. A pan-cancer analysis of the prognostic and immunological roles of matrix metalloprotease-1 (MMP1) in human tumors. Front Oncol. 2023 Jan 13;12:1089550. doi: 10.3389/fonc.2022.1089550. PMID: 36727076; PMCID: PMC9885257.
Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK, Varambally S. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia. 2017 Aug;19(8):649-658. doi: 10.1016/j.neo.2017.05.002. Epub 2017 Jul 18. PMID: 28732212; PMCID: PMC5516091.
Amukti DP, Wazni AR, Irham LM, Sulistyani N, Ma’ruf M, Adikusuma W, Sarasmita MA, Khairi S, Purwanto BD, Suyatmi S, Siswanto LM. Identifying pathogenic variants associated with Alzeimer by integrating genomic databases and bioinformatics approaches. InE3S Web of Conferences 2024 (Vol. 501, p. 01021). EDP Sciences.
Irham LM, Amukti DP, Adikusuma W, Singh D, Chong R, Basyuni M, et al. Applied of bioinformatics in drug discovery and drug development: bioinformatic analysis 1996-2024. In: BIO Web of Conferences. EDP Sciences; 2025.
Chandrashekar DS, Karthikeyan SK, Korla PK, Patel H, Shovon AR, Athar M, Netto GJ, Qin ZS, Kumar S, Manne U, Creighton CJ, Varambally S. UALCAN: An update to the integrated cancer data analysis platform. Neoplasia. 2022 Mar;25:18-27. doi: 10.1016/j.neo.2022.01.001. Epub 2022 Jan 22. PMID: 35078134; PMCID: PMC8788199.
Irham LM, Amukti DP, Adikusuma W, Singh D, Chong R, Basyuni M, et al. Applied of bioinformatics in drug discovery and drug development: bioinformatic analysis 1996-2024. In: BIO Web of Conferences. EDP Sciences; 2025.
Gumelar G, Ulfa MM, Amukti DP, Irham LM, Yuliani S, Adikusuma W, et al. Harnessing Genomic and Bioinformatic Data to Broaden Understanding of Leukaemia Across Continents. Scripta Medica (Banja Luka). 2024 Nov 1;55(6):717–25.
Prasetyaning Amukti D, Indah Pratami R, Gumelar G. Tinjauan Literatur tentang Hubungan Mutasi Genetik dengan Resistensi Obat pada Mycobacterium Tuberculosis. Journal of Pharmacy and Halal Studies [Internet]. 2024 Nov 28;2(1):6–12. Available from: https://journal.eduscience.co.id/index.php/JPHS/article/view/18
Dai L, Mugaanyi J, Cai X, Dong M, Lu C, Lu C. Comprehensive bioinformatic analysis of MMP1 in hepatocellular carcinoma and establishment of relevant prognostic model. Sci Rep. 2022 Aug 10;12(1):13639. doi: 10.1038/s41598-022-17954-x. PMID: 35948625; PMCID: PMC9365786.
Xi C, Song Z, Cui Q, Zhao Y, Li K, Kang H. Elevated MMP1 Expression in Carcinoma-Associated Fibroblasts of Breast Cancer Contributes to Tumor Progression and Unfavorable Prognosis. Ann Clin Lab Sci. 2024 Jan;54(1):66-75. PMID: 38514057.
Tian R, Li X, Gao Y, Li Y, Yang P, Wang K. Identification and validation of the role of matrix metalloproteinase-1 in cervical cancer. Int J Oncol. 2018 Apr;52(4):1198-1208. doi: 10.3892/ijo.2018.4267. Epub 2018 Feb 7. PMID: 29436615; PMCID: PMC5843389.
Poorolajal J, Nafissi N, Akbari ME, Mahjub H, Esmailnasab N, Babaee E. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study. Arch Iran Med. 2016 Oct;19(10):680-686. PMID: 27743431.
Amukti DP, Irham LM, Surono S, Adikusuma W, Chong R, El Khair R, et al. Genomic variants and epidemiology of atherosclerosis – worldwide correlation analysis and utilization of atherosclerosis gene variants for identification of drug target candidates with bioinformatics approach. Bulgarian Cardiology [Internet]. 2024 Dec 31;30(4):108–20. Available from: https://journal.bgcardio.org/article/145391/
Cheng X, Li Z, Jia X, Fan Z, He Q, Zhuang Z. TPD52 is a prognostic biomarker and potential therapeutic target for ER+/PR+/HER2+ breast cancer. Chin Clin Oncol. 2024 Jun;13(3):33. doi: 10.21037/cco-23-156. Epub 2024 Jun 1. PMID: 38859601.
Qi T, Hu Y, Wan J, Zhao B, Xiao J, Liu J, Cheng Y, Wu H, Lv Y, Ji F. Glioma-associated oncogene homolog 1 in breast invasive carcinoma: a comprehensive bioinformatic analysis and experimental validation. Front Cell Dev Biol. 2024 Oct 17;12:1478478. doi: 10.3389/fcell.2024.1478478. PMID: 39483334; PMCID: PMC11524909.
